Medical management of inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 1, 1999, Pages 15-25

  Ward, F M ^c   Bodger, K ^b   Daly, M J ^c   Heatley, R V ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b Clinical Department   (United Kingdom)

^c Duncan Building ^*

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; SALICYLIC ACID DERIVATIVE;

COST EFFECTIVENESS ANALYSIS; ENTERITIS; HEALTH ECONOMICS; HUMAN; LIFE EXPECTANCY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; COST BENEFIT ANALYSIS; COST OF ILLNESS; CROHN DISEASE; DISEASE MANAGEMENT; ECONOMICS; HEALTH CARE COST; PATIENT CARE; STATISTICS; ULCERATIVE COLITIS; UNITED KINGDOM; UNITED STATES;

COLITIS, ULCERATIVE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; CROHN DISEASE; DISEASE MANAGEMENT; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; PATIENT CARE MANAGEMENT; UNITED STATES;

EID: 0032615251     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00437.x     Document Type: Review

References (43)

1. 1 Calkins B, Mendeloff A. Epidemiology of inflammatory bowel disease. Epidemiol Rev 1986; 8: 60-91.
2. 2 Stowe S, Redmond S, Stormont J, et al. An epidemiologic study of inflammatory bowel disease in Rochester, New York. Gastroenterology 1990; 98: 104-16.
3. 3 Langman MJS. Epidemiological overview of inflammatory bowel disease. In: Allen RN, Rhodes JM, Hanauer SB, Keighley MRB, Alexander-Williams J, Fazio FW. Inflammmatory Bowel Disease, 3rd edn. New York: Churchill Livingstone, 1997.
4. 4 Forbes A. Epidemiology, aetiology and pathogenesis. In: Clinician's Guide to Inflammatory Bowel Disease, Chapter 1, pp. 1-37. London: Chapman & Hall Medical, 1997.
5. 5 Ekbom A, Helmick CG, Zack M, Holmberg L, Adami H-O. Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology 1992; 103: 954-60.
6. 6 Steinhart AH, et al Sulfasalazine and mesalazine for maintenance therapy of Crohn's Disease: a meta-analysis. Am J Gastroenterol 1994; 89: 2116-24.
7. 7 Sutherland LR. Sulfasalazine and the new salicylates. In: Allen RN, Rhodes JM, Hanauer SB, Keighley MRB, Alexander-Williams J, Fazio FW. Inflammmatory Bowel Disease, 3rd edn. New York: Churchill Livingstone, 1997.
8. 8 Bonapace CR, Mays DA. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease. Ann Pharmacother 1997; 31: 907-13.
9. 9 Stephen B, Hanauer MD. Inflammatory bowel disease. N Engl J Med 1996; 334: 841-8.
10. 10 D'Haens GR, Rutgeerts PJ. How should corticosteroids be used in inflammatory bowel disease. Clin Immunother 1996; 5: 334-40.
11. 11 Lofberg R, Danielsson A, Suhr O, Nilsson A, et al. Oral Budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996; 110: 1713-18.
12. 12 Greenberg GR, Feagan BG, Martin F, Sutherland LR., et al. for the Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn's disease. N Engl J Med 1994; 331: 836-41.
13. 13 Anon. Budesonide warrants consideration for treating acute exacerbations of inflammatory bowel disorders. Drugs Ther Perspect 1996; 7: 1-6.
14. 14 Greenberg GR, Feagan BG, Martin F., et al. and The Canadian Inflammatory Bowel Disease Study Group. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Gastroenterology 1996; 110: 45-51.
15. 15 Somerville KW, Langman MJ, Kane SP, MacGilchrist AJ, Watkinson G, Salmon P. Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: comparative trial of hydrocortisone acetate foam and prednisolone 21-phosphate enemas. Br Med J 1985; 291: 866.
16. 16 Christopher-Stevens A, Shah SA, Bousavaros A. Immunosuppressive agents in gastrointestinal disease. Immunology 1995; 11: 554-61.
17. 17 Kornbluth A, George J, Sachar D, B. Immunosuppressive drugs in Crohn's disease. Gastroenterologist 1994; 2: 239-46.
18. 18 Feagan BG, McDonald JWD, Rochon J, Laupacis A, et al. for the Canadian Crohn's Relapse Prevention trial investigators. Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994; 330: 1846-51.
19. 19 Bouhnik Y, Lemann M, Mary J-Y, Scemama G, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215-19.
20. 20 Feagan BG, Rochon J, Fedorak RN, Irvine EJ, et al. for the North American Crohn's Study Group investigators. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332: 292-7.
21. 21 Wexner SD, Glorsky SL. Quality of life after restorative proctocolectomy. In: Allen RN, Rhodes JM, Hanauer SB, Keighley MRB, Alexander-Williams J, Fazio FW. Inflammmatory Bowel Disease, 3rd edn. New York: Churchill Livingstone, 1997.
22. 22 Asman J, Koretz RL. Clinical economics review: Nutritional support. Aliment Pharmacol Ther 1997; 11: 453-71.
23. 23 Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995; 108: 1056-67.
24. 24 Eisen GM, Farmer, RG. Health-related quality of life in inflammatory bowel disease. Pharmacoeconomics 1996; 10: 327-35.
25. 25 Glise H, Hallerback B. Quality of life in gastrointestinal disease - reports from working groups and conclusions. J Gastroenterol 1993; 28(Suppl. 199): 47-9.
26. 26 Irvine, EJ. Quality of life - measurement in inflammatory bowel disease. Scand J Gastroenterol 1993; 28(Suppl. 199): 36-9.
27. 27 Steven C, Fullerton MPH. Health-related quality of life. Curr Opin Gastroenterol 1996; 12: 39-43.
28. 28 Irvine EJ, Feagan B, Rochon J, Archembeault A, et al. and the CCRPT Study Group. Quality of Life adds dimension to clinical trials in IBD. Gastroenterology 1994; 102: A640(Abstract).
29. 29 Singleton JW, Hanauer S, Robinson M. Quality of life results of double-blind placebo-controlled trial of mesalamine in patients with Crohn's Disease. Dig Dis Sci 1995; 40: 931-5.
30. 30 Archambault A, Feagan B, Fedorak R, et al. The Canadian Crohn's Relapse prevention trial. Gastroenterology 1991; 100: A193(Abstract).
31. 31 Pinchbeck BR, Kirdeikis J, Thomson, ABR. Economic impact of inflammatory bowel disease in Alberta. Can J Gastroenterol 1988; 2: 53-6.
32. 32 Binder V, Hendriksen C, Kreiner S. Prognosis in Crohns's disease based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 146-50.
33. 33 Hendriksen C, Kreiner S, Binders V. Long-term prognosis in ulcerative colitis based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 158-63.
34. 34 Hay JW, Hay AR. Inflammatory bowel disease: Costs of illness. J Clin Gastroenterol 1992; 14: 309-17.
35. 35 Hay AR, Hay JW. Inflammatory bowel disease; Medical cost algorithms. J Clin Gastroenterol 1992; 14: 318-27.
36. 36 Spivak W, Sockolow R, Rigas A. The relationship between insurance class and severity of presentation of inflammatory bowel disease in Children. Am J Gastroenterol 1995; 90: 982-7.
37. 37 Probert CSJ, Mayberry JF. Inflammatory bowel disease; Patient expectations in the 1990s. J Soc Med 1991; 84: 131-2.
38. 38 Moody, A, Mayberry JF. Life Insurance and Inflammatory Bowel Disease: Is there discrimination against patients? Int J Colorect Dis 1996; 11: 276-8.
39. 39 Beck T, Leddin DJ, Lemire SE, et al. Insurance rating of patients with inflammatory bowel disease: Report of a conference on morbidity and mortality. Can J Gastroenterol 1994; 8: 438-45.
40. 40 Travis SP. Review article: insurance risks for patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther 1997; 11: 51-9.
41. 41 Mayberry MK, Probert C, Srivastava E, Rhodes J, Mayberry JF. Perceived descrimination in education and employment by people with Crohn's disease: a case control study of educational achievement and employment. Gut 1992; 33: 312-14.
42. 42 Sutherland LR, Ramcharan S, Bryant H, Fick G. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990; 98: 1123-8.
43. 43 Monthly Index of Medical Specialities. London: Haymarket Publishing Services Ltd, May 1998.